BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics, Inc. - Special Call Transcript

Jul 20, 2020 / 12:30PM GMT
Release Date Price: €59 (+37.85%)
Operator

Hello and welcome to the BioXcel Therapeutics conference call. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions)

It's now my pleasure to turn the call over to CEO, Vimal Mehta. Please go ahead, sir.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Thank you, operator. Good morning, everyone, and thank you for joining our conference call today to discuss the top line results from our 2 pivotal Phase III SERENITY trial. We appreciate everyone's time and attention, and hope that you and your loved ones are staying safe. A press release announcing these results crossed the wire earlier today and is available on BioXcel Therapeutics website.

As a reminder, we will be making forward-looking statements regarding our financial outlook in addition to regulatory product development and commercialization plan. Such forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, and actual results may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot